UPCC 27423 V-RULES: Vyxeos Real-world US Long-term Effectiveness and Safety Study
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
This is a retrospective, non-interventional, multi-center, single-arm, observational study of patients with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) who have been treated with Vyxeos in real world clinical practice and managed as per the healthcare providers discretion. The study will collect pseudonymized patient data abstracted from medical records.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
09 Mar 2024.
Study ID: 854405
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
